H+Trace is a Miami-based technology company founded in 2021 that develops an AI-powered traceability platform for healthcare and logistics supply chains. Its core product, Contactless MultiSense (CMS), is a hardware-software system that tracks, monitors, and predicts issues in sensitive shipments like lab samples, organ transplants, and pharmaceuticals without opening packaging, addressing over $34B in annual temperature-related losses.[1][2][3] Serving clinical labs, hospitals, pharmaceuticals, Clinical Research Organizations (CROs), and logistics firms, H+Trace solves critical problems in sample handling—such as misdiagnosis risks from errors, waste, and inefficiencies—by automating prioritization, flagging abnormalities, and enabling predictive analytics.[2][3] With over 11 million samples tracked, partnerships across Latin America (including Siemens Healthineers), and U.S. expansion underway via pilots with labs and hospitals, the seven-person team shows strong growth momentum from its Argentine origins.[1][2]
H+Trace emerged from a personal tragedy: CEO Javier Cuello, a serial entrepreneur with expertise in drones and public sector innovation, launched the company after a close friend suffered a misdiagnosis at a top Argentine hospital due to sample handling errors.[2] Cuello's investigation revealed a "huge blind spot" in pre-testing logistics, shifting focus from diagnostics to upstream prevention.[2] Co-founder Ivan Fardjoume, an IoT-specialized electronic technician from Buenos Aires with experience at firms like Ebers and NETI, brought hardware expertise to build the CMS prototype.[1] Starting in Argentina's Innovation Park, the company relocated headquarters to Miami for U.S. scaling, raised funding from investors like Techstars Global, Mountain Top Holdings, and Andes Finance, and quickly gained traction with real-world deployments in organ transplants and ice cream logistics.[1][2]
H+Trace rides the AI-driven supply chain optimization wave, particularly in healthcare logistics amid rising demands for precision medicine, cold-chain integrity for biologics, and post-pandemic lab efficiency.[2][3] Timing aligns with global market forces like $34B+ annual losses from temperature failures and regulatory pressures for traceable pharma distribution, amplified by U.S. expansion from Latin America.[1][2] By influencing the ecosystem through CMS prototypes with Agentic AI and pilots in hospitals/research institutions, H+Trace modernizes error-prone pre-testing processes, rebuilds diagnostic trust, and enables scalable applications from national labs to at-home kits, positioning it as a key enabler in predictive healthcare tech.[2][3]
H+Trace is poised for accelerated U.S. growth through hospital/lab pilots and Siemens partnerships, with Agentic AI prototypes signaling deeper automation.[2] Trends like AI-blockchain hybrids for data security, expanding cold-chain needs for gene therapies/vaccines, and global logistics digitization will propel it toward dominance as the "smartest shipment" predictor.[3][6] Its influence may evolve from niche healthcare solver to broad logistics platform, potentially integrating with at-home diagnostics and CROs worldwide—transforming how medical decisions protect lives, much like Cuello's personal mission to eliminate the "blind spot" that sparked it all.[2]
H+Trace has raised $500K in total across 1 funding round.
H+Trace's investors include Right Side Capital Management, Techstars.
H+Trace has raised $500K across 1 funding round. Most recently, it raised $500K Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $500K Seed | Right Side Capital Management, Techstars |
